Kedarisetty Suraj, Tint Derrick, Michael Alexander, Soliman Ahmed M S
Department of Otolaryngology - Head and Neck Surgery Lewis Katz School of Medicine at Temple University Philadelphia Pennsylvania USA.
Laryngoscope Investig Otolaryngol. 2021 Jan 28;6(1):13-20. doi: 10.1002/lio2.511. eCollection 2021 Feb.
To determine the demographics, presentation, management, and outcomes of patients with recurrent angioedema. To compare the findings to patients with ACE inhibitor related angioedema.
Retrospective case series with chart review of patients who presented to a tertiary-care hospital between January 2010 and December 2017 with two or more episodes of angioedema. Excluded were patients with anaphylactic reaction, medication induced angioedema, or angioedema secondary to an infectious etiology. A group of 88 patients who presented during the same time period with ACE inhibitor related angioedema was used as a control. Statistical analysis was conducted using a two-tailed Fisher exact test and a multivariate logistical regression model to determine significant associations.
Ninety-one patients were identified; 61 met the selection criteria and had 217 total episodes of angioedema episodes presenting to the emergency department. Fifty percent were Caucasian or Hispanic. The average number of episodes was 3.5 (range: 2-23). The lips and tongue were the most commonly affected sites (37% and 39%). The larynx and floor of mouth were least likely to be involved (7% and 6%). Only 1 patient was found to have C1 esterase inhibitor deficiency. Twenty-eight percent of patients had asthma, allergic rhinitis, food allergies, or atopic dermatitis. Only 11% of episodes required airway intervention. No patients required airway intervention after admission.
Recurrent angioedema was primarily idiopathic, was less severe than ACE inhibitor angioedema, and was associated with an atopic history. There was less frequent worsening of symptoms after admission, and recurrences occurred more frequently are at the same anatomic subsite.
IV.
确定复发性血管性水肿患者的人口统计学特征、临床表现、治疗及预后。并将结果与血管紧张素转换酶(ACE)抑制剂相关性血管性水肿患者进行比较。
回顾性病例系列研究,对2010年1月至2017年12月期间在一家三级医院就诊的血管性水肿发作两次或更多次的患者进行病历审查。排除有过敏反应、药物性血管性水肿或感染性病因继发的血管性水肿患者。选取同期出现ACE抑制剂相关性血管性水肿的88例患者作为对照。采用双侧Fisher精确检验和多因素逻辑回归模型进行统计分析,以确定显著相关性。
共识别出91例患者;61例符合入选标准,共有217次血管性水肿发作就诊于急诊科。50%为白种人或西班牙裔。发作平均次数为3.5次(范围:2 - 23次)。嘴唇和舌头是最常受累部位(分别为37%和39%)。喉和口底受累可能性最小(分别为7%和6%)。仅1例患者发现C1酯酶抑制剂缺乏。28%的患者有哮喘、过敏性鼻炎、食物过敏或特应性皮炎。仅11%的发作需要气道干预。入院后无患者需要气道干预。
复发性血管性水肿主要为特发性,比ACE抑制剂相关性血管性水肿病情轻,且与特应性病史有关。入院后症状恶化频率较低,复发更常发生在相同的解剖亚部位。
IV级